Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2016) Mark C. Genovese et al.   Arthritis & Rheumatology

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

(2015) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

(2015) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

(2015) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

(2014) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Less Jak2 makes more platelets

(2014) R. C. Skoda   BLOOD

The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing

(2014) David T Felson et al.   ARTHRITIS RESEARCH & THERAPY

Janus kinase inhibitors in autoimmune diseases

(2013) John J O'Shea et al.   ANNALS OF THE RHEUMATIC DISEASES

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

(2013) Tom W J Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Interferon- 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes

(2008) A. Yamane et al.   BLOOD